Ingels Helene Andrea Sinclair
Neisseria and Streptococcus Reference Centre Department of Microbiological Surveillance and Research, Statens Serum Institut, Artillerivej 5, 2300 Copenhagen, Denmark.
Dan Med J. 2015 Jul;62(7).
Streptococcus pneumoniae is still a leading cause of septicaemia, pneumonia and meningitis in young children world-wide with over half a million children dying annually from pneumococcal disease. Some children are prone to repeated episodes of invasive pneumococcal disease (IPD) because of an underlying predisposing disease. Recurrent IPD (rIPD) is a rarity and published reports on rIPD are limited by having few children included, selected groups of patients or short follow-up periods. Deficiencies in the innate or adaptive immune system have been described in children with rIPD, but the frequency of immunodeficiency among such patients is unknown. The aim of this PhD thesis was to examine paediatric cases of laboratory-confirmed rIPD, over a 33-year period in Denmark, to determine risk factors and study aspects of the immunological background for this problem in children. In October 2007, a seven-valent pneumococcal conjugate vaccine (PCV7) was implemented in the Danish infant immunization programme. An additional aim of the thesis was to examine the impact of vaccination on a population level, following the first three years of general PCV7 vaccination in Denmark. The thesis consists of three papers, which are all directly or indirectly based on data retrieved from the National Streptococcus Pneumoniae Registry. This registry is nationwide and dates back to 1938. The registry contains data from all laboratory-confirmed cases of IPD in Denmark and is continually updated for national surveillance. In Paper 1, we conducted a 33-year retrospective nationwide study of paediatric rIPD. By using data from the National Streptococcus Pneumoniae Registry combined with clinical data from hospital records, we could describe one of the largest known cohorts of children (n:59) with rIPD . We covered epidemiological, microbiological, and clinical features of this clinical entity. Of all children experiencing rIPD, 47% had a known predisposing underlying disease at the time of the rIPD. Most common was immune deficiency due to transplantation. In 19% the episode of rIPD was the clinical manifestation that subsequently led to a diagnosis of an underlying disease. Finally, in 31% of the children no underlying disease was detected. Paper 2 covers data from a follow-up of the cohort of children described in Paper 1. Of this unselected cohort of rIPD, all children without an obvious underlying disease predisposing to pneumococcal disease (such as malignancy, HIV or cerebrospinal-fluid leakage) were invited to participate in the study by undergoing a thorough immunological evaluation. Basic immunological parameters including activity of complement-pathways and T-, B-, NK-cell count were examined in the children and their families. Furthermore, B-cell function including antibody response to polysaccharide-based pneumococcal vaccination and somatic hypermutation was evaluated. Toll like receptor (TLR) signalling function was evaluated in a functional assay. When children with classical risk factors for IPD were excluded, 15 individuals were eligible. Of whom, sex (40%) children with complement C2 deficiency were identified. Moreover, impaired vaccination response was found in six children: three with concurrent C2 deficiency and three with no other immune abnormality. One patient with a severe TLR signalling dysfunction was diagnosed. In Paper 3, we aimed to assess the impact of PCV7 in Denmark following the first three years of infant immunization. By comparing age-specific disease incidences of IPD in the pre-PCV7 (years 2000-2007) and the PCV7 periods (years 2008-2010) we sought to assess direct and indirect effects on incidence of IPD. In addition, changes in pneumococcal serotype distribution and IPD-related mortality were assessed. We documented a marked decline in the incidence of IPD in both vaccinated and non-vaccinated age groups. The overall incidence of IPD among children aged 0-5 years declined from 26.7 to 16.3 cases per 100,000 (IRR 0.58; 95% confidence interval (CI) [0.48-0.69]). A minor but statistically significant increase in the incidence of IPD due to non-vaccine type IPD was observed in both vaccinated and non-vaccinated groups, but with predominance of serotypes covered by the higher valence pneumococcal conjugate vaccines. This thesis confirms the existing knowledge on underlying diseases predisposing children to IPD, such as cerebrospinal fluid leakage, congenital heart disease and malignant diseases. Our findings support the notion that rIPD in a child should prompt a thorough search for an underlying disease. Moreover, our results underline that rIPD in a child without a known predisposing disease is a major pointer towards primary immune deficiency, such as complement deficiency and B cell dysfunction. This is in line with the guidelines put forward by various specialist committees. Finally, we reported data from the first three years of PCV7 vaccination in the Danish immunization programme, suggesting that the vaccine is effective against all serotypes included in the vaccine when administered in a 2+1 schedule.
肺炎链球菌仍是全球幼儿败血症、肺炎和脑膜炎的主要病因,每年有超过50万儿童死于肺炎球菌疾病。一些儿童由于潜在的易感疾病,容易反复发生侵袭性肺炎球菌疾病(IPD)。复发性IPD(rIPD)较为罕见,关于rIPD的已发表报告因纳入儿童数量少、患者选择群体或随访期短而受到限制。rIPD儿童存在先天性或适应性免疫系统缺陷,但此类患者中免疫缺陷的发生率尚不清楚。本博士论文的目的是研究丹麦33年间实验室确诊的rIPD儿科病例,以确定风险因素并研究儿童这一问题的免疫背景。2007年10月,丹麦婴儿免疫计划中实施了七价肺炎球菌结合疫苗(PCV7)。该论文的另一个目的是在丹麦全面接种PCV7疫苗的头三年之后,研究疫苗在人群层面的影响。该论文由三篇论文组成,均直接或间接基于从国家肺炎链球菌登记处检索到的数据。该登记处覆盖全国,可追溯到1938年。该登记处包含丹麦所有实验室确诊的IPD病例数据,并持续更新以进行国家监测。在论文1中,我们对儿科rIPD进行了一项为期33年的全国性回顾性研究。通过使用国家肺炎链球菌登记处的数据并结合医院记录中的临床数据,我们能够描述已知最大的rIPD儿童队列之一(n = 59)。我们涵盖了这一临床实体的流行病学、微生物学和临床特征。在所有经历rIPD的儿童中,47%在rIPD发生时患有已知的潜在易感基础疾病。最常见的是移植导致的免疫缺陷。在19%的病例中,rIPD发作是随后导致潜在疾病诊断的临床表现。最后,在31%的儿童中未检测到潜在疾病。论文2涵盖了对论文1中描述的儿童队列进行随访的数据。在这个未经过筛选的rIPD队列中所有没有明显易患肺炎球菌疾病的潜在基础疾病(如恶性肿瘤、HIV或脑脊液漏)的儿童被邀请通过接受全面的免疫评估来参与研究。对这些儿童及其家庭检查了包括补体途径活性和T、B、NK细胞计数在内的基本免疫参数。此外,还评估了B细胞功能,包括对基于多糖的肺炎球菌疫苗的抗体反应和体细胞超突变。通过功能试验评估了Toll样受体(TLR)信号传导功能。排除具有IPD经典风险因素的儿童后,有15人符合条件。其中,发现40%的儿童存在补体C2缺乏。此外,在6名儿童中发现疫苗接种反应受损:3名同时存在C2缺乏,3名无其他免疫异常。诊断出1名严重TLR信号传导功能障碍患者。在论文3中,我们旨在评估丹麦婴儿接种PCV7疫苗头三年之后PCV7的影响。通过比较PCV7之前(2000 - 2007年)和PCV7期间(2008 - 2010年)IPD的年龄特异性疾病发病率,我们试图评估对IPD发病率的直接和间接影响。此外,还评估了肺炎球菌血清型分布和IPD相关死亡率的变化。我们记录了接种疫苗和未接种疫苗年龄组中IPD发病率的显著下降。0 - 5岁儿童中IPD的总体发病率从每10万人26.7例降至16.3例(发病率比0.58;95%置信区间[0.48 - 0.69])。在接种疫苗和未接种疫苗的群体中均观察到非疫苗型IPD导致的IPD发病率有轻微但具有统计学意义的增加,但以更高价肺炎球菌结合疫苗覆盖的血清型为主。本论文证实了关于使儿童易患IPD的基础疾病的现有知识,如脑脊液漏、先天性心脏病和恶性疾病。我们的数据支持这样一种观点,即儿童的rIPD应促使对潜在疾病进行全面排查。此外,我们的结果强调,没有已知易感疾病的儿童发生rIPD是原发性免疫缺陷(如补体缺乏和B细胞功能障碍)的一个主要指标。这与各专业委员会提出的指南一致。最后,我们报告了丹麦免疫计划中PCV7疫苗接种头三年的数据,表明该疫苗按照2 + 1程序接种时对疫苗中包含的所有血清型均有效。